ForeSENTIA: Prostate
ForeSENTIA Prostate panel tests for single nucleotide variants, insertions, deletions, copy number alterations, and rearrangements in 36 genes which are commonly found in prostate cancers. Prostate cancer is the 2nd most common cancer in men and arises from the cells in the prostate gland. Prostate cancer initiates from the accumulation of mutations that will cause the healthy cells of the prostate to transform into malignant cells and divide uncontrollably. Mutations in genes such as AR, TP53, BRCA1, and BRCA2 are only some examples of genes that are frequently mutated in prostate cancer patients. Therefore, screening for the mutations responsible for cancer progression enables the identification of FDA/EMA-approved therapies tailored for each patient.
Microsatellite instability (MSI), which can optionally be tested in this panel, has been detected in patients with prostate cancer and can be used as an immunotherapy biomarker for men with advanced prostate cancer. The FDA-approved drug pembrolizumab can be used as an immunotherapy option for MSI-high patients.
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Are you a patient?
Certified laboratories
